Thierry S, Fautrel B, Lemelle I, Guillemin F. Prevalence and incidence of juvenile idiopathic arthritis: A systematic review. Jt Bone Spine. 2014;81:112–7.

Google Scholar 

Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–78.

CAS  PubMed  Google Scholar 

Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–49.

PubMed  Google Scholar 

Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol. 2004;31:390–2.

PubMed  Google Scholar 

Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, et al. 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis. Arthritis Rheumatol. 2022;74:553–69 (John Wiley and Sons Inc).

PubMed  Google Scholar 

Cimaz R, Marino A, Martini A. How I treat juvenile idiopathic arthritis: A state of the art review. Autoimmun Rev Elsevier. 2017;16:1008–15.

Google Scholar 

Viswanathan V, Murray KJ. Management of Children with Juvenile Idiopathic Arthritis. Indian J Pediatr Springer India. 2016;83:63–70.

Google Scholar 

Giancane G, Alongi A, Rosina S, Tibaldi J, Consolaro A, Ravelli A. Recent therapeutic advances in juvenile idiopathic arthritis. Best Pract Res Clin Rheumatol. 2017;31:476–87 (Baillière Tindall).

PubMed  Google Scholar 

Clarke SLN, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol. 2016;14:27 (BioMed Central).

Google Scholar 

Anink J, Otten MH, Gorter SL, Prince FHM, van Rossum MAJ, van den Berg JM, et al. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab? Rheumatology. 2013;52:1674–9 (Narnia).

CAS  PubMed  Google Scholar 

Ravelli A, Consolaro A, Horneff G, Laxer RM, Lovell DJ, Wulffraat NM, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–28. https://doi.org/10.1136/annrheumdis-2018-213030.

Tarkiainen M, Tynjälä P, Vähäsalo P, Kröger L, Aalto K, Lahdenne P. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial. Pediatr Rheumatol. 2019;17:80 (BioMed Central).

Google Scholar 

Oen K, Guzman J, Dufault B, Tucker LB, Shiff NJ, Duffy KW, et al. Health-Related Quality of Life in an Inception Cohort of Children With Juvenile Idiopathic Arthritis: A Longitudinal Analysis. Arthritis Care Res (Hoboken). 2018;70:134–44 (John Wiley & Sons, Ltd).

Google Scholar 

Consolaro A, Giancane G, Schiappapietra B, Davì S, Calandra S, Lanni S, et al. Clinical outcome measures in juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2016;14:23 (BioMed Central).

PubMed  PubMed Central  Google Scholar 

Swart J, Giancane G, Horneff G, Magnusson B, Hofer M, Alexeeva E, et al. Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries. Arthritis Res Ther. 2018;20:285 (BioMed Central).

PubMed  PubMed Central  Google Scholar 

Giancane G, Swart JF, Castagnola E, Groll AH, Horneff G, Huppertz H-I, et al. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Res Ther. 2020;22:71 (BioMed Central).

PubMed  PubMed Central  Google Scholar 

van Straalen JW, Giancane G, Amazrhar Y, Tzaribachev N, Lazar C, Uziel Y, et al. A clinical prediction model for estimating the risk of developing uveitis in patients with juvenile idiopathic arthritis. Rheumatology. 2021;60:2896–905 (Oxford Academic).

PubMed  Google Scholar 

van Straalen JW, Krol RM, Giancane G, Panaviene V, Ailioaie LM, Doležalová P, et al. Increased incidence of inflammatory bowel disease on etanercept in juvenile idiopathic arthritis regardless of concomitant methotrexate use. Rheumatology (Oxford). 2022;61(5):2104–12. https://doi.org/10.1093/rheumatology/keab678.

Ruperto N, Martini A. Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child. 2011;96:596–601 (BMJ Publishing Group Ltd).

PubMed  Google Scholar 

Bovis F, Consolaro A, Pistorio A, Garrone M, Scala S, Patrone E, et al. Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology. Rheumatol Int. 2018;38:5–17 (Springer Verlag).

PubMed  PubMed Central  Google Scholar 

Filocamo G, Consolaro A, Schiappapietra B, Dalprà S, Lattanzi B, Magni-Manzoni S, et al. A new approach to clinical care of juvenile idiopathic arthritis: the Juvenile Arthritis Multidimensional Assessment Report. J Rheumatol. 2011;38:938–53.

PubMed  Google Scholar 

Trincianti C, Van Dijkhuizen EHP, Alongi A, Mazzoni M, Swart JF, Nikishina I, et al. Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis. Arthritis Rheumatol (Hoboken, NJ). 2021;73:1966–75.

Google Scholar 

Kang J, Chan W, Kim M-O, Steiner PM. Practice of causal inference with the propensity of being zero or one: assessing the effect of arbitrary cutoffs of propensity scores. Commun Stat Appl Methods. 2016;23:1–20 (NIH Public Access).

CAS  PubMed  PubMed Central  Google Scholar 

Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat Wiley-Blackwell. 2011;10:150–61.

Google Scholar 

Hawley S, Ali MS, Cordtz R, Dreyer L, Edwards CJ, Arden NK, et al. Impact of TNF inhibitor therapy on joint replacement rates in rheumatoid arthritis: a matched cohort analysis of BSRBR-RA UK registry data. Rheumatology (Oxford). 2019;58:1168–75 (Oxford University Press).

CAS  PubMed  PubMed Central  Google Scholar 

Sarmanova A, Doherty M, Kuo C, Wei J, Abhishek A, Mallen C, et al. Statin use and risk of joint replacement due to osteoarthritis and rheumatoid arthritis: a propensity-score matched longitudinal cohort study. Rheumatology. 2020;59:2898–907 (Oxford Academic).

PubMed  Google Scholar 

Kubo S, Nakayamada S, Nakano K, Hirata S, Fukuyo S, Miyagawa I, et al. Comparison of the efficacies of abatacept and tocilizumab in patients with rheumatoid arthritis by propensity score matching. Ann Rheum Dis. 2016;75:1321–7 (BMJ Publishing Group Ltd).

CAS  PubMed  Google Scholar 

Chen J-F, Hsu C-Y, Yu S-F, Ko C-H, Chiu W-C, Lai H-M, et al. The impact of long-term biologics/target therapy on bone mineral density in rheumatoid arthritis: a propensity score-matched analysis. Rheumatology (Oxford). 2020;59:2471–80 (Oxford University Press).

CAS  PubMed Central  Google Scholar 

Takahashi N, Kojima T, Kida D, Kaneko A, Hirano Y, Fujibayashi T, et al. Concomitant methotrexate has little effect on clinical outcomes of abatacept in rheumatoid arthritis: a propensity score matching analysis. Clin Rheumatol Springer. 2019;38:2451–9.

Google Scholar 

White IR, Royston P, Wood AM. Multiple imputation using chained equations: Issues and guidance for practice. Stat Med. 2011;30:377–99 (John Wiley & Sons, Ltd).

PubMed  Google Scholar 

Clifton L, Clifton DA. The correlation between baseline score and post-intervention score, and its implications for statistical analysis. Trials. 2019;20:43 (BioMed Central).

PubMed  PubMed Central  Google Scholar 

Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transplant. 2020;55:675–80 (Nature Publishing Group).

CAS  PubMed  Google Scholar 

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL https://www.R-project.org/. 2019.

Rypdal V, Glerup M, Songstad NT, Bertelsen G, Christoffersen T, Arnstad ED, et al. Uveitis in Juvenile Idiopathic Arthritis: 18-Year Outcome in the Population-based Nordic Cohort Study. Ophthalmology. 2021;128:598–608 (Elsevier Inc).

PubMed  Google Scholar 

Anink J, Otten MH, Prince FHM, Hoppenreijs EPAH, Wulffraat NM, Swart JF, et al. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register. Rheumatology (Oxford). 2013;52:712–7.

CAS  Google Scholar 

Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int. 2009;30:229–38 (Springer).

CAS  PubMed  Google Scholar 

Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, et al. Experiences with tumour necrosis factor- inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry. Rheumatology. 2011;50:1337–40 (Oxford Academic).

CAS  PubMed  Google Scholar 

Bergman M, Patel P, Chen N, Jing Y, Saffore CD. Evaluation of Adherence and Persistence Differences Between Adalimumab Citrate-Free and Citrate Formulations for Patients with Immune-Mediated Diseases in the United States. Rheumatol Ther. Springer; 2020;1–10.

Windschall D, Horneff G. Safety and efficacy of etanercept and adalimumab in children aged 2 to 4 years with juvenile idiopathic arthritis. Clin Rheumatol. 2016;35:2925–31 (Springer).

CAS  PubMed  Google Scholar 

Horneff G, Klein A, Klotsche J, Minden K, Huppertz H-I, Weller-Heinemann F, et al. Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. Arthritis Res Ther. 2016;18:272 (BioMed Central).

PubMed  PubMed Central  Google Scholar 

Giménez-Roca C, Iglesias E, Torrente-Segarra V, Bou R, Sánchez-Manubens J, Calzada-Hernández J, et al. Efficacy and safety of TNF-alpha antagonists in children with juvenile idiopathic arthritis who started treatment under 4 years of age. Rheumatol Int. 2015;35:323–6 (Springer).

PubMed  Google Scholar 

Walters HM, Pan N, Lehman TJA, Adams A, Kalliolias GD, Zhu YS, et al. The impact of disease activity and tumour necrosis factor-α inhibitor therapy on cytokine levels in juvenile idiopathic arthritis. Clin Exp Immunol. 2016;184:308–17 (Wiley-Blackwell).

CAS  PubMed  PubMed Central  Google Scholar 

Alexeeva E, Dvoryakovskaya T, Denisova R, Sleptsova T, Isaeva K, Chomahidze A, et al. Comparative Efficacy of Adalimumab and Etanercept in Children with Juvenile Idiopathic Arthritis Under 4 Years of Age Depending on Active Uveitis. Open Rheumatol J. 2019;13:1–8.

CAS  Google Scholar 

Klotsche J, Niewerth M, Haas J-P, Huppertz H-I, Zink A, Horneff G, et al. Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). Ann Rheum Dis. 2016;75:855–61 (BMJ Publishing Group Ltd).

CAS  PubMed  Google Scholar 

Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(10):1839–49. https://doi.org/10.1093/rheumatology/kez030.

de Lalouvière LLH, Ioannou Y, Fitzgerald M. Neural mechanisms underlying the pain of juvenile idiopathic arthritis. Nat Rev Rheumatol. 2014;10:205–11 (Nature Publishing Group).

Google Scholar 

Consolaro A, Giancane G, Alongi A, van Dijkhuizen EHP, Aggarwal A, Al-Mayouf SM, et al. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. Lancet Child Adolesc Heal. 2019;3:255–63.

Google Scholar 

Kearsley-Fleet L, Vicente González L, Steinke D, Davies R, De Cock D, Baildam E, et al. Methotrexate persistence and adverse drug reactions in patients with juvenile idiopathic arthritis. Rheumatology (Oxford). 2019;58:1453 (Oxford University Press).

CAS  PubMed Central  Google Scholar 

Haasnoot AJW, van Tent-Hoeve M, Wulffraat NM, Schalij-Delfos NE, Los LI, Armbrust W, et al. Erythrocyte Sedimentation Rate as Baseline Predictor for the Development of Uveitis in Children With Juvenile Idiopathic Arthritis. Am J Ophthalmol. 2015;159:372-377.e1 (Elsevier).

PubMed  Google Scholar